Takeda Pharmaceutical: The latest presentation of Phase 2b data for TAK-861 SLEEP 2024 showed clinically significant effects of an oral orexin agonist in NT1.

JPX · Jun 3 18:45

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.